Worldwide, Salmonella Typhi infections persist as an important health problem, accounting for about 9.4 million cases annually. Porins are one of the targets in the protective response against infection with Salmonella Typhi, a vaccine designed with these porins was shown to be safe in a phase 1 clinical trial eliciting a long-lasting response. In this work, an airlift bioreactor was designed and used to produce Salmonella Typhi biomass and purify porins. A comparison between the airlift bioreactor and shaken flasks biomass production rates was carried out considering a constant oxygen mass transfer coefficient. The analysis showed that the change in culture system does not affect the growth kinetic parameters, nor the maximum biomass production. The growth and substrate consumption kinetic parameters were estimated through mathematical models. Porins produced in the bioreactor induced equivalent humoral responses and protective capacity in mice compared to porins produced in shaken flasks. These results suggest that airlift bioreactors provide a promising platform for industrial production of porins.